Partnering
Establishing research collaborations is central to Ansaris' business model. We are committed to building relationships and forming partnerships with pharmaceutical and biotechnology companies with the goal of utilizing our technology platform to discover novel therapeutics.
Ansaris has established or successfully concluded collaborations with Ono Pharmaceutical, Novartis, Lilly, Amgen, Speedel, Scios, P&G Pharmaceuticals, Dow AgroSciences, and DuPont.
Ansaris is the ideal partner to solve small discovery drug discovery challenges
Our technology platform has evolved over the last ten years based on technology licensed from Sarnoff Corporation and acquired from Protein Mechanics, Inc. This robust platform combines a torsion-space algorithm for building better protein models with in silicofragment-based libraries and world-class computational chemists to design breakthrough drug candidates in any therapeutic area. Our approach has enabled the advancement of numerous "stalled" programs by identifying new protein forms and novel binding sites including competitive and allosteric sites on enzymes and hotspots for protein-protein interactions. The platform has been successfully applied to generate therapeutics in oncology, inflammation, infectious diseases, and cardiovascular disease, including a second-generation renin inhibitor and a highly-selective p38 kinase inhibitor.
We foster collaborative team structures to effectively and efficiently prosecute difficult programs. We offer flexible partnership structures and welcome the opportunity to share our novel approach to today's intractable drug targets.